Kymera Therapeutics target price raised to $140 from $130 by Leerink Partners
KYMR•Leerink Partners raised its target price for Kymera Therapeutics to $140 from $130.
Related News
EQT Corporation: Stifel raises target price to $71 from $66
EQT•
Norwegian Cruise Line: Stifel raises target price to $24 from $22
NCLH•
LCI Industries announces special shareholder meeting to vote on Patrick merger
LCII•
Federal Realty Q3 core FFO rises 6% year over year to $1.87 per diluted share
FRT•
L3Harris Technologies target price raised to $335 from $318 by Bernstein
LHX•